Abeona Therapeutics shareholders elect Goldan, Zeiher as Class 1 directors

• Abeona Therapeutics held its annual stockholder meeting on June 12, 2026.
• Stockholders backed the selection of Keith A. Goldan, Bernhardt G. Zeiher, M.D. as Class 1 directors.
• Deloitte & Touche was ratified as independent registered public accounting firm for fiscal 2026.
• Stockholders authorized raising shares reserved under the 2023 equity incentive plan to 11,500,000 from 8,400,000.
• An amendment to remove the advance notice provision for director nominations failed to win the required supermajority.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-028458), on June 12, 2026, and is solely responsible for the information contained therein.